Prognostic value of the “dynamic” second revision of the international staging system (R2- ISS) in patients with multiple myeloma undergoing anti-CD38 antibody, carfilzomib, and dexamethasone therapy

Kikuchi T; Tsukada N; Kunisada K; Matsumoto C; Nomura-Yogo M; Oda Y; Sato K; Takei T; Ogura M; Abe Y

doi:10.21203/rs.3.rs-4113413/v1

Prognostic value of the “dynamic” second revision of the international staging system (R2- ISS) in patients with multiple myeloma undergoing anti-CD38 antibody, carfilzomib, and dexamethasone therapy

Identifier:nobleid.org/w1/20260526/90F2DFDD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/90F2DFDD.svg?ark=w1%2F20260526%2F90F2DFDD)](https://nobleid.org/work/w1/20260526/90F2DFDD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Prognostic value of the “dynamic” second revision of the international staging system (R2- ISS) in patients with multiple myeloma undergoing anti-CD38 antibody, carfilzomib, and dexamethasone therapy

Identifier:nobleid.org/w1/20260526/90F2DFDD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/90F2DFDD.svg?ark=w1%2F20260526%2F90F2DFDD)](https://nobleid.org/work/w1/20260526/90F2DFDD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work